Printer Friendly

FIRST NONSURGICAL LASER TREATMENT OF RAPID HEARTBEAT PERFORMED; ANGEION ABLATION SYSTEM OFFERS CURE

 MINNEAPOLIS, March 8 /PRNewswire/ -- For the first time physicians used laser catheter ablation in a nonsurgical procedure to successfully cure a patient suffering from life-threatening ventricular tachycardia, an abnormally rapid heartbeat. This less invasive procedure used Minneapolis-based Angeion Corporation's (NASDAQ: ANGN) laser catheter ablation system.
 The patient, a 56-year-old male underwent the procedure last week at the Carolinas Medical Center in Charlotte, N.C. The patient had suffered a heart attack six years ago and had been on medication.
 "We are very pleased with the results of this case," said Dr. Robert H. Svenson, principal investigator for Angeion's clinical trials and medical director of the Laser and Applied Technologies Laboratory at the Carolinas Heart Institute. "The patient has gone home and is no longer on heart medication for this problem. Our initial follow-up studies indicate that this nonsurgical laser ablation procedure is encouraging. Long-term follow-up will be required to assess long-term efficacy of the therapy."
 Ventricular tachycardia affects more than 1.4 million Americans. It is one of the most common causes of death, killing approximately 450,000 adults each year.
 Angeion's nonsurgical treatment involves threading a specially designed catheter through the femoral artery in the groin up into the left ventricle of the heart. The catheter maps the inside of the heart to identify the areas that are sending conflicting electrical impulses and causing the heart to beat too rapidly. After the critical areas are identified the catheter is secured in place inside the heart. A small amount of laser energy is directed to neutralize these critical areas. A sensor at the tip of the laser catheter monitors the tissue temperature and controls laser delivery. Once the abnormal areas are neutralized, physicians try to induce ventricular tachycardia to gauge the effectiveness of the procedure. After completion of the procedure, the laser catheter device is removed.
 Angeion, through its AngeLase subsidiary, has been developing this device as an alternative to current treatments: drugs, permanently implanted defibrillators and complex open heart surgery. Research completed to date indicates that Angeion's laser catheter ablation system may also offer a cure for ventricular tachycardia. While various ablation technologies have achieved success in treating atrial arrhythmias (upper chambers), these technologies have not been as successful in the ventricles or pumping chambers of the heart.
 Angeion Corporation is developing electrophysiological devices to treat various types of arrhythmias, irregular heartbeats. In addition to the laser catheter ablation system, Angeion is also developing a fourth generation implantable defibrillator and a new concept in external temporary pacing. Angeion is also traded on the Boston Stock Exchange under the symbol ANI.
 -0- 3/8/93
 /NOTE: Illustrations of procedure are available/
 /CONTACT: Brenda Roth of Angeion Corporation, 612-550-9388/
 (ANGN)


CO: Angeion Corporation ST: Minnesota IN: MTC SU:

KH -- MN003 -- 3928 03/08/93 10:46 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 8, 1993
Words:466
Previous Article:WISCONSIN CENTRAL REPAYS NOTES, DEBT TOTALING $33.3 MILLION
Next Article:DECISION DATA SIGNS SUPPORT NET AS MANAGING VAR
Topics:


Related Articles
ANGEION RECEIVES FDA APPROVAL TO BEGIN CLINICAL TRIALS; TO TEST LASER CATHETER FOR NONSURGICAL TREATMENT OF RAPID HEARTBEATS
ANGEION PERFORMS FIRST PRE-CLINICAL IMPLANTATION OF ITS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; RECEIVES ALLOWANCE ON TWO IMPORTANT PATENTS
ANGEION REPORTS FIRST QUARTER RESULTS
ANGEION INITIATES CLINICAL TRIALS IN UNITED KINGDOM
ANGEION RECEIVES FDA AUTHORIZATION TO CONDUCT CLINICAL TRIALS
ANGEION REPORTS FIRST U.S. IMPLANT OF SENTINEL ICD
Angeion Initiates Clinical Trials of AngeCool RF Catheter Ablation System
Medtronic Begins U.S. and European Evaluation of New Ablation Catheter to Help Heart Attack Victims
Angeion Corporation Receives CE Approval for Model 2020 Series of ICDs
Angeion Receives Pre-Market Approval from FDA for Sentinel ICDs; Compact, Feature Intensive ICDs to be Marketed to $960 Million U.S. Industry

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters